Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. The company's management will participate in a fireside chat, which will be available via live webcast on Cartesian's website. An archived replay will also be accessible for a limited time in the Events section at www.cartesiantherapeutics.com.

News Market Reaction – RNAC

-2.30%

1 alert

-2.30% News Effect

On the day this news was published, RNAC declined 2.30%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET.

A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Investor Contact

Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact

David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

When is Cartesian Therapeutics (RNAC) presenting at the H.C. Wainwright BioConnect Conference?

Cartesian Therapeutics will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, at 9:00 a.m. ET.

Where can I watch Cartesian Therapeutics' (RNAC) presentation at the H.C. Wainwright Conference?

The presentation can be watched via live webcast in the Events section of Cartesian Therapeutics' website at www.cartesiantherapeutics.com.

What is Cartesian Therapeutics' (RNAC) main focus area?

Cartesian Therapeutics is a clinical-stage biotechnology company that specializes in developing cell therapy for autoimmune diseases.

Will Cartesian Therapeutics' (RNAC) H.C. Wainwright presentation be available for replay?

Yes, an archived replay of the presentation will be available for a limited time in the Events section of the company's website.